LARGE-SCALE cGMP FACILITY

Built to Advance Bacterial Therapeutics

List Labs is on track to provide fully integrated end-to-end service for innovators of microbiome therapeutics (LBPs) with a new 130,000 sq ft, state-of-the-art, commercial CDMO facility by Q4, 2024. List Labs is directing the design and construction of the expansion via the establishment of new provisional sister company, List Biotherapeutics.

INVESTORS

INNOVATORS

NEW CDMO FACILITY

PHASE III / COMMERCIAL

130,000 SQ FT

FISHERS, INDIANA

ONLINE BY 2024

NEW CDMO FACILITY

PHASE III / COMMERCIAL

130,000 SQ FT

FISHERS, INDIANA

ONLINE BY 2024

VISION FOR THE FUTURE

Invested in Premium Phase III & Commercial Contract Manufacturing

South Korea-based Genome & Company (KOSDAQ 314130) has made a significant investment into List Labs and List Biotherapeutics, with plans to attract further investment and grow the company’s strong legacy position in microbiome therapeutics – specifically with construction of the new Phase III & Commercial CDMO facility on 17 acres in Fishers, Indiana.

As a pioneer in clinical manufacturing for LBP-based therapeutics, List Labs has a strong pipeline of clients that need state-of-the-art Phase III and commercial manufacturing. With this growth-oriented investment strategy and an additional therapeutics pipeline from Genome & Company, List Labs is seeking to build on 40 years of expertise to become the microbiome therapeutic sector’s leading CDMO.

More To Explore

CDMO Services: Greater Capacity and End-to-End LBP Manufacturing

List Labs is one of the most experienced CDMOs, with the vision of harnessing bacteria’s potential for a healthier world. Our expertise is now embodied within the engineering of our new Phase III / Commercial facility that will support innovators in this exciting area.

Leading Experience in Applications for Live Bacteria

The use of Live Biotherapeutic Products (LBPs) to reintroduce beneficial microorganisms has the potential to provide transformative therapies that improve lives. List Labs is uniquely positioned as one of the most experienced CDMOs, delivering leading-edge therapies to patients around the globe.

Investors

Partnering